ABSTRACT
Keywords: multiple myeloma; bone disease; osteogenesis; adipogenesis; adipose-derived stem cells; bone marrow; senescence; Dickkopf-related protein 1; systemic disease.
Subject(s)
Intercellular Signaling Peptides and Proteins/metabolism , Mesenchymal Stem Cells/metabolism , Multiple Myeloma/metabolism , Osteoblasts/metabolism , Aged , Aged, 80 and over , Cell Differentiation , Cells, Cultured , Cellular Senescence , Humans , Mesenchymal Stem Cells/pathology , Middle Aged , Osteoblasts/pathology , OsteogenesisABSTRACT
The generation in vitro of cultured red blood cells (cRBC) could become an alternative to classical transfusion products. However, even when derived from healthy donors, the cRBC generated in vitro from hematopoietic stem cells may display alterations resulting from a poor controlled production process. In this context, we attempted to monitor the quality of the transfusion products arising from new biotechnologies. For that purpose, we developed an in vitro erythrophagocytosis (EP) test with the murine fibroblast cell line MS-5 and human macrophages (reference method). We evaluated 38 batches of cRBC, at the stage of reticulocyte, generated from CD34(+) cells isolated from placental blood or by leukapheresis. We showed that (i) the EP test performed with the MS-5 cell line was sensitive and can replace human macrophages for the evaluation of cultured cells. (ii) The EP tests revealed disparities among the batches of cRBC. (iii) The viability of the cells (determined by calcein-AM test), the expression of CD47 (antiphagocytosis receptor) and the externalization of phosphatidylserine (PS, marker of phagocytosis) were not critical parameters for the validation of the cRBC. (iv) Conversely, the cell deformability determined by ektacytometry was inversely correlated with the intensity of the phagocytic index. Assuming that the culture conditions directly influence the quality of the cell products generated, optimization of the production mode could benefit from the erythrophagocytosis test.
Subject(s)
Erythrocytes/cytology , Animals , CD47 Antigen/analysis , Cells, Cultured/chemistry , Cells, Cultured/cytology , Cells, Cultured/physiology , Erythrocyte Aging , Erythrocyte Deformability , Erythrocyte Membrane/chemistry , Erythrocyte Transfusion , Erythrocytes/chemistry , Erythropoiesis , Fibroblasts/physiology , Fluoresceins/analysis , Fluorescent Dyes/analysis , Hematopoietic Stem Cells/cytology , Humans , Leukapheresis , Macrophages/physiology , Membrane Lipids/analysis , Mice , Phagocytosis , Phosphatidylserines/analysis , Reticulocytes/cytologyABSTRACT
In vitro RBC production from stem cells could represent an alternative to classic transfusion products. Until now the clinical feasibility of this concept has not been demonstrated. We addressed the question of the capacity of cultured RBCs (cRBCs) to survive in humans. By using a culture protocol permitting erythroid differentiation from peripheral CD34(+) HSC, we generated a homogeneous population of cRBC functional in terms of their deformability, enzyme content, capacity of their hemoglobin to fix/release oxygen, and expression of blood group antigens. We then demonstrated in the nonobese diabetes/severe combined immunodeficiency mouse that cRBC encountered in vivo the conditions necessary for their complete maturation. These data provided the rationale for injecting into one human a homogeneous sample of 10(10) cRBCs generated under good manufacturing practice conditions and labeled with (51)Cr. The level of these cells in the circulation 26 days after injection was between 41% and 63%, which compares favorably with the reported half-life of 28 ± 2 days for native RBCs. Their survival in vivo testifies globally to their quality and functionality. These data establish the proof of principle for transfusion of in vitro-generated RBCs and path the way toward new developments in transfusion medicine. This study is registered at http://www.clinicaltrials.gov as NCT0929266.
